These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 485716)

  • 21. Cardiac biomarkers and survival in haemodialysis patients.
    Sommerer C; Beimler J; Schwenger V; Heckele N; Katus HA; Giannitsis E; Zeier M
    Eur J Clin Invest; 2007 May; 37(5):350-6. PubMed ID: 17461980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis.
    Burmeister JE; Scapini A; da Rosa Miltersteiner D; da Costa MG; Campos BM
    Nephrol Dial Transplant; 2007 Apr; 22(4):1184-9. PubMed ID: 17272314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parathyroid hormone in patients with diabetes mellitus and end-stage renal disease on chronic haemodialysis.
    Pabico RC; Rivero AJ; McKenna BA; Freeman RB
    Proc Eur Dial Transplant Assoc; 1983; 19():221-6. PubMed ID: 6878235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid abnormalities associated with end-stage renal disease.
    Liu J; Rosner MH
    Semin Dial; 2006; 19(1):32-40. PubMed ID: 16423180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidative stress in haemodialysis.
    Loughrey CM; Young IS; Lightbody JH; McMaster D; McNamee PT; Trimble ER
    QJM; 1994 Nov; 87(11):679-83. PubMed ID: 7820542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease.
    Reuter SE; Evans AM; Faull RJ; Chace DH; Fornasini G
    Ann Clin Biochem; 2005 Sep; 42(Pt 5):387-93. PubMed ID: 16168195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid determination of atenolol in human plasma and urine by high-pressure liquid chromatography.
    Weddle OH; Amick EN; Mason WD
    J Pharm Sci; 1978 Jul; 67(7):1033-5. PubMed ID: 660497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood-potassium in patients undergoing haemodialysis.
    Goldner MG; Bleicher SJ; Spergel G
    Lancet; 1969 Mar; 1(7594):575-6. PubMed ID: 4179866
    [No Abstract]   [Full Text] [Related]  

  • 29. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis.
    Davis MR; Pham CU; Cies JJ
    J Antimicrob Chemother; 2021 Feb; 76(3):822-825. PubMed ID: 33152758
    [No Abstract]   [Full Text] [Related]  

  • 30. Prolonged elevation of vancomycin concentrations in a patient with end-stage renal disease.
    Amodio MI; Monane M; Klein RS
    South Med J; 1990 Jan; 83(1):77-8. PubMed ID: 2300843
    [No Abstract]   [Full Text] [Related]  

  • 31. [Determination in biologic media of a new beta-blocker, atenolol, by high performance liquid chromatography].
    Decourt S; Flouvat B
    J Chromatogr; 1979 Jun; 174(1):258-63. PubMed ID: 546890
    [No Abstract]   [Full Text] [Related]  

  • 32. Clearance of middle molecules during haemodialysis and haemodiafiltration: new insights.
    Leypoldt JK; Holmes CJ; Rutherford P
    Nephrol Dial Transplant; 2012 Dec; 27(12):4245-7. PubMed ID: 23235952
    [No Abstract]   [Full Text] [Related]  

  • 33. The final word.
    La Greca G; Klinkmann H; Valderrábano F; Zucchelli P
    Kidney Int Suppl; 2000 Aug; 76():S156-9. PubMed ID: 10936813
    [No Abstract]   [Full Text] [Related]  

  • 34. The analysis of atenolol in plasma using an automated sample preparation technique.
    Dale AD; Turner SE
    J Pharm Biomed Anal; 1990; 8(8-12):1055-8. PubMed ID: 2100586
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of end-stage kidney disease: medical aspects.
    Briggs WA
    Mil Med; 1975 Sep; 140(9):606-8. PubMed ID: 808764
    [No Abstract]   [Full Text] [Related]  

  • 36. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
    Bouchard J; Shepherd G; Hoffman RS; Gosselin S; Roberts DM; Li Y; Nolin TD; Lavergne V; Ghannoum M;
    Crit Care; 2021 Jun; 25(1):201. PubMed ID: 34112223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of atenolol--a review.
    Kirch W; Görg KG
    Eur J Drug Metab Pharmacokinet; 1982; 7(2):81-91. PubMed ID: 6749509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ketoprofen in treating primary dysmenorrhea.
    Gleeson S; Sorbie J
    Can Med Assoc J; 1983 Oct; 129(8):842-4. PubMed ID: 6351994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease.
    Rosseel MT; Bogaert MG; Christiaens M; Verpooten GA; De Broe ME
    Arch Int Pharmacodyn Ther; 1979 May; 239(1):176. PubMed ID: 485716
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.